Safety and Efficacy of the Extracorporeal Ventricular Assist System in Car Diogenic Shock: A Prospective, Multicenter , Single-Arm Study

NCT07769528 | Recruiting

• 1 other identifier: YRX-XSFZ-001
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Study Title: Safety and Efficacy of Extracorporeal Ventricular Assist System for Cardiogenic Shock: A Prospective, Multicenter, Single-Arm Clinical Study Objective: To evaluate the safety and efficacy of temporary mechanical circulatory support and bridge therapy with an extracorporeal ventricular assist system in patients with cardiogenic shock or weaning failure from cardiopulmonary bypass, and to comprehensively assess the device, pump head, cannulae and tubing. Pilot Phase: Clinical validation of Class III medical device. Study Design: Prospective, multicenter, single-arm target-value design. Sample Size: 40 patients. Primary Endpoint: Success rate of mechanical circulatory support. Secondary Endpoints: 30-day survival after transition to long-term therapy (VAD/transplant); 30-day cardiovascular mortality after device explantation; MACCE incidence; Mean support duration; Incidence of bleeding, thrombosis, hematologic events, acute renal/hepatic dysfunction, infection; Hemodynamic trends during support; Changes in SCr, BUN, ALT, TBIL at use, discharge and 30 days post-explantation vs baseline; Device satisfaction. Follow-up: Within 6 hours of initiation, during support, 24 hours, 7 days, 30 days post-explantation/transition, and at discharge. All clinical data were collected, managed and analyzed by an independent data and statistical center and clinical monitoring unit to support safety/efficacy evaluation and market approval.

Conditions

Cardiogenic Shock

Outcome Measures

Primary Outcomes (1)

• Success rate of extracorporeal mechanical circulatory support using the investigational extracorporeal ventricular assist system

  30-day survival following explantation of the extracorporeal ventricular assist system

  30-day

Study Arms (1)

EVAS Treatment Group

EXPERIMENTAL

Procedure: EVAS Treatment

Interventions

EVAS Treatment PROCEDURE

Using interventional implantation of blood conduits into the left cardiac system, an extracorporeal pump shunts blood to the arterial system to partially or fully substitute cardiac pumping function and sustain systemic circulation.

EVAS Treatment Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• (4) Cardiogenic shock shall meet the following criteria:
• Signs of inadequate perfusion (at least one item):
• ① Altered mental status unexplainable by other causes: agitation in the early stage, lethargy and stupor in the late stage;
• Cool, clammy and mottled skin of extremities; ③ Oliguria (\<30 mL/h or 0.5 mL/kg/h).
• Hypotension with adequate intravascular volume (at least one item):
• Systolic blood pressure ≤90 mmHg or mean arterial pressure ≤60 mmHg lasting more than 30 minutes; ② Requirement for vasoactive agents or inotropic agents to maintain systolic blood pressure ≥90 mmHg; ③ Systolic blood pressure ≥90 mmHg after excluding trauma, intoxication, hypoxia and other factors, accompanied by obvious manifestations of hypoperfusion.
• Laboratory or hemodynamic findings (at least one item):
• Hemodynamics: Cardiac Index (CI) ≤2.2 L/min·m², Pulmonary Capillary Wedge Pressure (PCWP) ≥15 mmHg;
• Laboratory test: Lactate ≥2 mmol/L; ③ Serum creatinine increased to 1.5 times the baseline value, or glomerular filtration rate decreased by \>50%; ④ ALT elevated to 3 times the upper limit of normal. (5) Authorized clinicians confirm that all feasible measures have been implemented to correct abnormalities of arterial blood gas, electrolyte disorders, hypovolemia, hypervolemia, bradycardia, arrhythmia and incomplete rewarming.

You may not qualify if:

• (1) Patients who fail to comply with medical treatment protocols; (2) Patients with established irreversible central nervous system injury; (3) Patients intolerant to anticoagulants (such as heparin or equivalent alternatives); (4) Patients with severe infection, malignant tumor, or end-stage multiple organ failure; (5) Patients with implanted mechanical heart valves, moderate to severe aortic regurgitation, or unrepaired structural cardiac lesions (e.g., ventricular septal rupture); (6) Patients with severe peripheral vascular disease or irreversible neurological/neuromuscular disorders; (7) Patients with pulmonary embolism, pulmonary infarction, or uncorrectable pulmonary hypertension; (8) Patients with psychiatric disorders requiring long-term standardized treatment or relevant medical history, drug abusers, and patients positive for HIV or syphilis; (9) Patients with a history of stroke or transient ischemic attack (TIA) within the past 3 months; (10) Patients with active bleeding or disorders of coagulation; (11) Female patients during pregnancy; (12) Patients who have participated in another clinical trial within 1 month, or are currently participating in another clinical trial that has not reached its endpoint; (13) Patients with other conditions deemed ineligible for this trial by the investigator.

Sponsors & Collaborators

• China National Center for Cardiovascular Diseases: lead

Study Sites (1)

Fuwai Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100000, China

RECRUITING

MeSH Terms

Conditions

Shock, Cardiogenic

Condition Hierarchy (Ancestors)

Myocardial Infarction; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis; Shock

Central Study Contacts

xianqiang wang

CONTACT

13331006960; wangxianqiang@fuwai.com

haibo chen

CONTACT

189 1017 1249; 18910171249@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 13, 2026
• First Posted: August 18, 2026
• Study Start: March 23, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: August 18, 2026

Record last verified: 2026-08

Locations

CN (1)